HMPV Diagnostics Market Size, Share, and Industry Analysis, By Product Type (Reagents & Consumables and Instruments), By Test Type (Point-of-Care Tests and Laboratory Tests), By Technology (Molecular Diagnostics, Immunoassays, Microbiology, and Others), By Method (Conventional and Automated), By End-user (Hospitals & Clinics, Diagnostic Centers, and Others), and Regional Forecast, 2025-2032

The global HMPV diagnostics market is experiencing considerable growth, primarily driven by technological advancements in diagnostic methods and increasing disease prevalence, which demand the early detection of the disease. Moreover, the rising awareness of HMPV (human metapneumovirus) among healthcare providers and patients is also expected to boost the adoption of testing products, which is further expected to contribute to market growth.

• For instance, as per an update issued by the Ministry of Health and Family Welfare (MoHFW) in January 2025, the Central Government of India instructed the states to strengthen information, education, and communication (IEC) campaigns to educate the public about HMPV transmission and prevention.

Such campaigns are bolstering the demand for early disease diagnosis, which is further expected to boost the market growth.

HMPV Diagnostics Market Driver

Increasing Incidence of Respiratory Infections to Boost Market Growth

Currently, the rising incidence of respiratory infections such as HMPV, particularly among vulnerable populations such as infants and the elderly, is a significant driver for the adoption of HMPV testing products. This necessitates early and accurate diagnostic tools to manage and treat these conditions effectively. Such a scenario is expected to boost market growth in the coming years.

• For instance, according to data published by the World Health Organization (WHO) in January 2025, in several countries in the Northern Hemisphere, the trends in acute respiratory infections increased at this time of year, with seasonal epidemics of respiratory pathogens and common respiratory viruses, including HMPV, as well as mycoplasma pneumonia. This is anticipated to boost the demand for HMPV testing, driving market growth.

Request a Free sample to learn more about this report.

According to data published by Frontiers Media S.A., in 2022, the detection rate of HMPV was 4.68% at the Guangzhou Women and Children's Medical Center (GWCMC), depicting significant growth over 0.32% in 2013.

HMPV Diagnostics Market Restraint

Lack of Skilled Professionals May Hamper Market Growth

Despite its high popularity, the adoption of advanced diagnostic technologies, such as PCR-based tests and multiplex panels, is limited by their high costs. This is particularly challenging for healthcare facilities in resource-limited settings, where the affordability of sophisticated testing technologies is a barrier to widespread implementation. This may hinder market growth over the coming years.

• For instance, according to data released by Springer Nature Limited in 2021, the costs of reagents for PCR are high and the technique requires sophisticated laboratory equipment and trained personnel, which may pose a greater challenge to some healthcare settings, hindering market growth.

HMPV Diagnostics Market Opportunity

Innovations in HMPV Diagnostics May Spur Market Expansion

Innovations in diagnostic technologies, including polymerase chain reaction (PCR) methods and next-generation sequencing (NGS), enhance the sensitivity and specificity of HMPV detection. These advancements allow for quicker results and more reliable diagnostics, which are crucial for timely medical intervention and may present lucrative opportunities for market growth.

• For instance, according to the Journal of Virological Methods, in December 2023, researchers developed a real-time RT-PCR assay that can detect and identify the two major subgroups of hMPV (A and B) in one tube. Such developments improving diagnostic accuracy may propel the market expansion in the near future.

Segmentation

Key Insights

The report covers the following key insights:

• Incidence of HMPV, By Key Countries, 2024


• Overview: Technological Advancements in HMPV Diagnostics


• Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches)


• Impact of COVID-19 on the Market

Analysis by Product Type

On the basis of product type, the market is subdivided into reagents & consumables and instruments.

The reagents & consumables segment is expected to hold a major share of the global market. The surging demand for reagents and consumables in HMPV diagnosis is driven by their cost-effectiveness, flexibility, rapid turnaround times, ease of use, and alignment with the increasing demand for point-of-care testing, which is expected to propel the segment's growth.

• For instance, as of 2025, TestSea Labs HMPV antigen test kit, a point-of-care diagnostic tool for healthcare providers, demonstrates results in just 15-20 minutes. This test provides accurate results for HMPV in a short time and eliminates the need for specialized laboratory equipment, which is driving product demand and contributing to the segment growth.

Analysis by Test Type

Based on test type, the market is subdivided into point-of-care tests and laboratory tests.

The point-of-care tests segment is expected to hold a significant share of the global market during the forecast period. The segment growth can be attributed to its growing utilization for respiratory infections such as HMPV due to its rapid results and ease of use.

• For instance, according to an article published by the National Center for Biotechnology Information (NCBI) in March 2024, the key aspect of the POCT topic is the importance of time. POCT offers a quicker turnaround compared to traditional laboratory tests, which is anticipated to boost its demand for HMPV testing, propelling the segment growth.

Analysis by Technology

On the basis of technology, the market is divided into molecular diagnostics, immunoassays, microbiology, and others.

The molecular diagnostics segment is expected to hold a significant share of the global market during the forecast period. Molecular diagnostic tests, particularly RT-PCR and real-time PCR, are recognized for their exceptional sensitivity and accuracy in detecting hMPV infections. These methods can identify low viral loads, which is crucial for timely diagnosis and is thereby expected to boost the segment growth.

• For instance, as per an article published by MDPI in January 2025, reverse transcription PCR is recognized as the gold standard for HMPV diagnosis due to its high sensitivity and specificity.

Such high significance of this technology is anticipated to boost the segment growth.

Analysis by Method

Based on method, the market is subdivided into conventional and automated.

The automated segment is expected to grow substantially during the forecast period. The growth can be attributed to the rapid and sensitive detection of HMPV without the need for extensive manual intervention, which makes them suitable for use in various clinical environments.

• For instance, as per an article published by Springer Nature Limited in August 2020, researchers developed the Simprova Molecular Diagnostic System, a fully automated system used to detect human metapneumovirus (hMPV), among other respiratory viruses, by utilizing a technique called Loop-mediated Isothermal Amplification (LAMP) to analyze samples and provide results within a short timeframe rapidly. This makes it a suitable choice for point-of-care settings, which is expected to boost the segment growth.

Analysis by End-user

By end-user, the market is fragmented into hospitals & clinics, diagnostic centers, and others.

The diagnostic laboratories segment is projected to expand at the fastest CAGR during the projection period. The growth is mainly attributed to the increasing purchase rate of HMPV testing kits by diagnostic laboratories due to the sudden outbreak of HMPV cases in some regions globally.

• For instance, in January 2025, IGGMCH molecular diagnostic lab ordered 100 PCR kits for the testing of samples for the suspected HMPV cases.

The rising purchase of testing products for HMPV is projected to boost the segment growth.

Regional Analysis

To gain extensive insights into the market, Request for Customization

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for the largest share of the global HMPV diagnostics market in 2024. The region's growth can be attributed to the high incidence of acute respiratory infections due to HMPV, most particularly among children in the U.S., which may boost the demand for HMPV diagnostic products.

• For instance, a recent study published by the Conversation in April 2023 reported that 25 years of collected data found HMPV as the second-common cause of lung infection in children.

Europe is the second-largest market based on the demand for HMPV diagnostics. The growth is attributed to the significant presence of key players and well-established healthcare infrastructure supporting the diagnostic rate of HMPV in the region.

The Asia Pacific is expected to grow at the highest CAGR during the forecast period. The region's growth can be attributed to the surge in the transmission of HMPV cases in China, which is highly boosting the diagnosis rate and propelling the use of testing products.

• For instance, the Chinese Center for Disease Control and Prevention has reported a significant rise in respiratory viral infections, particularly human metapneumovirus (HMPV), across northern China since December 2024. This is driving the high demand for diagnostic testing products, spurring the regional market growth.

Key Players Covered

The global HMPV diagnostics market is consolidated, with many companies offering various test types. The report includes the profiles of the following key players:

• LKC Technologies, Inc. (U.S.)


• QuidelOrtho Corporation (U.S.)


• ARUP Laboratories (U.S.)


• Diasorin (Italy)


• Seegene, Inc. (South Korea)


• ZeptoMetrix (U.S.)


• R-Biopharm AG (Germany)


• Thermo Fisher Scientific Inc. (U.S.)


• TestSea Labs (China)


• Torontech, Inc. (Canada)

Key Industry Developments

• In January 2025, Bangalore Medical College and Research Institute (BMCRI) announced its plan to establish South India's first Infectious Disease Research and Diagnostic Laboratory (IRDL), as announced by the medical education department. BMCRI has also started testing samples for Human Metapneumovirus, focusing on vulnerable populations.


• In March 2024, Agilus Diagnostics, a diagnostic laboratory chain based in India, announced its collaboration with SEAS International LLC to create a state-of-the-art referral laboratory in Oman, which may support the HMPV testing rate globally.